Navigation Links
U.S. Patent Office Grants Biomoda Registration for Trademarks

ALBUQUERQUE, N.M., Sept. 22 /PRNewswire-FirstCall/ -- Biomoda, Inc. (OTC Bulletin Board: BMOD) (, a development stage medical diagnostics company, expanded its intellectual property portfolio with approval from the U.S. Patent and Trademark Office for its Trademarks CyDx(R) and CyPath(R).

"We are pleased to receive these two new trademark protected names for our product portfolio," said John Cousins, Biomoda president. "It is a big milestone for us to achieve sales and meet the metrics for getting these registered trademarks. CyDx(R) and CyPath(R) are particularly powerful and memorable names and will help to differentiate our cancer diagnostic assays."

Biomoda's innovative, non-invasive technology is designed for early lung cancer screening of large populations at a reasonable cost. With the technology, clinicians can identify cancerous or aberrant cells extracted from samples of sputum. When exposed to CyPath(R), cancerous cells in sputum glow red under fluorescent light and can be detected under a microscope.

Biomoda, with funding provided through the New Mexico Institute of Mining and Technology and the New Mexico Department of Veterans Services, is currently conducting a clinical study using Biomoda's proprietary testing technology for detection of early lung cancer in the veterans. The New Mexico state legislature allocated $1.6 million in funding for the screening program.

Lung cancer claims more lives than any other cancer. The expected five-year survival rate for all patients diagnosed with lung cancer is 15 percent; the five-year survival rate for cases detected when the disease is still localized is 50 percent. Presently, only 16 percent of lung cancer cases are diagnosed at this early stage.

Biomoda's technology was originally developed at Los Alamos National Laboratory.

For more information contact:

John Cousins

Biomoda, Inc.


Forward Looking Statement

All statements in this press release that are not historical are forward-looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of BIOMODA's products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. BIOMODA, Inc. expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in BIOMODA's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.

SOURCE Biomoda, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. U.S. District Court in Delaware Reinstates Damage Awards to Cordis Corporation on Patents Infringed by Medtronic, Inc. and Boston Scientific Corporation
2. Delft University of Technology patent for manufacturing radio isotopes
3. Court Rejects Two Medtronic Patents
4. WaterPure International, Inc. and Everest Water Ltd. Revise Payment Terms of Patent License to Produce Water From Air
5. NuVasive Announces Patent Infringement Complaint Brought by Medtronic Sofamor Danek
6. Urigen Announces Issuance of Key Patent for URG101 - A Novel Therapy to Treat Painful Bladder Syndrome/Interstitial Cystitis
7. Dr. Ajrawats Air-Pulse Autonomic Meditation Therapy, a Revolutionary, Scientific, Meditation Therapy, Receives Patent Trademark
8. Watson Announces District Court Ruling in Naproxen Sodium Patent Suit
9. SpectraScience Awarded Patent for Correcting Image Misalignment
10. Barr Announces Agreements to Settle Mirapex(R) and Aggrenox(R) Patent Challenges
11. USPTO Issues Patent Embodying Methodologies for Abating a Broad Range of Allergens, Pathogens, Viruses, Bacteria, Odors and Volatile Organic Compounds.
Post Your Comments:
(Date:11/29/2015)... ... November 29, 2015 , ... ... unique analog distortion effect tool designed specially for Final Cut Pro X. ... limiltess looks with the easy-to-use modification controls. Destoying and creating chaotic distortion is ...
(Date:11/28/2015)... ... , ... Trying to relax on a couch can actually be uncomfortable, so ... design due to personal experience with a bad back," he said. , This easy-to-use, ... well as increases support. It also makes it easier to eat, do other activities ...
(Date:11/27/2015)... ... November 27, 2015 , ... According to an ... the University of Toronto and the University of British Columbia suggested that laws requiring ... injuries. The article explains that part of the reason for the controversial conclusion is ...
(Date:11/27/2015)... , ... November 27, 2015 , ... ... the toilets were," said an inventor from Hillside, N.J. "Many people catch diseases ... cover so that individuals will always be protected from germs." , He developed ...
(Date:11/27/2015)... , ... November 27, 2015 , ... ... of progress through sharing, the 2016 Building Better Radiology Marketing Programs ... will begin on Sunday, March 6, 2016, at Caesars Palace in Las Vegas ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... November 26, 2015 ... addition of the  "2016 Future Horizons ... Therapeutic Drug Monitoring (TDM) Market: Supplier ... Emerging Opportunities"  report to their offering.  ... announced the addition of the  "2016 ...
(Date:11/26/2015)... , November 26, 2015 ... of the "Radioimmunoassay Market by Type ... Pharmaceutical Industry, Academics, Clinical Diagnostic Labs), Application ... Forecast to 2020" report to their ... announced the addition of the "Radioimmunoassay ...
(Date:11/25/2015)...  Amgen (NASDAQ: AMGN ) today announced the ... the United States (U.S.) Food and ... to Humira ® (adalimumab). Amgen believes this submission ... FDA and represents Amgen,s first BLA submission using the ... M.D., executive vice president of Research and Development at ...
Breaking Medicine Technology: